HER2+ Breast Cancer: Applying Recent Data Updates at ASCO 2024 into Clinical Practice - Episode 9
Overview of DESTINY-Breast06
Aditya Bardia, MD, MPH, shares comprehensive insights on the DESTINY-Breast06 study evaluating T-DXd in HER2-low and HER2 ultra-low metastatic breast cancer, and the panel offers its initial impressions.
Video content above is prompted by the following questions:
- Briefly discuss the DESTINY-Breast06, including study design, primary endpoints, and safety:
- DESTINY-Breast06 evaluating T-DXd vs investigators choice of chemotherapy in HER2-low, HR+ mBC.
- Based on the above data, how might this impact practice patterns in HER2-low and HER2 ultra-low disease?
- Would the avail of first-line T-DXd for HER2-low and HER2 ultra-low patients influence your approach in the number of regimens of endocrine therapy you recommend to patients?
- DESTINY-Breast06 evaluating T-DXd vs investigators choice of chemotherapy in HER2-low, HR+ mBC.
Related Content:
